Analyst Explains Why He’s Investing in This Top Biotech ETF
“But this is a subsector that’s been under the mat for quite some time. So it’s nice to see some price action there. So couple things for me.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Leucadia National Ian Cumming And Joseph Steinberg | 302,307 | $51,044,505 | +1% | 0.35% |
| 2. | Bronte Capital John Hempton | 69,265 | $11,695,395 | -5% | 1.16% |
| 3. | Bailard Inc Thomas Bailard | 5,462 | $922,259 | -2% | 0.02% |
| 4. | Fisher Asset Management Ken Fisher | 2,268 | $382,981 | -18% | 0% |
| 5. | Hurley Capital Charles Goldblum | 341 | $57,578 | +52% | 0.03% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,226,668 | $207,122,859 | 0.06% | |
| 2. | 814,290 | $137,492,866 | 0.02% | |
| 3. | 724,989 | $122,414,422 | 0.03% | |
| 4. | 666,343 | $112,512,008 | 0.15% | |
| 5. | 648,103 | $109,439,535 | 2.64% |